Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IGXT exploding $5+ Stock trading at laughable 70 pennies
IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus
http://www.insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-is-todays-pharma-focus/116698/
Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it.
IGXT exploding $5+ Stock trading at laughable 70 pennies
IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus
http://www.insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-is-todays-pharma-focus/116698/
Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it.
IGXT exploding $5+ Stock trading at laughable 70 pennies
IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus
http://www.insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-is-todays-pharma-focus/116698/
Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it.
IGXT-DD UPDATE // LIFETIME OPPORTUNITY HERE
Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there are another partnering discussion ongoing for 2 Drugs .Their unique Thin-film version of the Blockbuster Drug Cialis (Erectile Dysfunction) alone is worth $2-3 per share , NDA filing for the Drug expected in early Q1 2017.
IGXT has a ridiculous Market Cap of US$43 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL
Intelgenx (IGXT) (IGX.V)
Market Cap: $43 Million
Cash: $7.1 Million << 2 Years of Cash
Price: $0.69
Burn-Rate: ~$400k per Quarter
Shares Out : 63.6 Million
Upcoming Milestones :
Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q1/2017
•Expected USA launch Q2/2017
Product :Tadalafil (Erectile Dysfunction)
•505(b)(2) USA NDA submission in Q1/2017
•Expected USA launch Q4/2017
Wafer Viagra For Instant Results One of the big challenges for erectile dysfunction medicine manufacturers is to quicken the time between the application of the medicine and its response. Men want instant results when they take Viagra, Cialis or Levitra and complain that having to wait as much as thirty minutes before the active ingredient is effective can burst the bubble of spontaneity and passion which are often essential requirements of good sex. Well a solution could be at hand following research done by a Canadian research company called IntelGenx who have developed wafers [like the common breath freshness ones] that are designed to melt on your tongue which they say will get the medicine into your bloodstream around 30% faster than by using conventional tablets. IntelGenx say that because the mouth is lined with tiny blood vessels applying the wafer Viagra here can give a very fast application of the drug directly into the bloodstream. IntelGenx said that they would be conducting more clinical trials to corroborate this and they hoped to develop a whole range of fast acting wafer medications to treat not only erectile dysfunction but also pain relief, depression and hypertension. Sometimes men complain that if they have eaten a large meal it can take an even longer time for the Viagra, Cialis and Levitra to take effect. If on the other hand they made use of erectile dysfunction medication in a wafer form applied directly to the mouth and therefore bypassing their digestive system this problem would disappear. Using a wafer type of Viagra would also mean that you wouldn't have to go and get a glass of water in the middle of a passionate encounter in order to swallow your pill. Wafer Viagra would be a much more discreet application of impotence medication and Ukmedix News will be looking out for updates on the IntelGenx clinical testing done on this new idea
-----
IntelGenx to Initiate Phase 1 Trial of Montelukast
IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.
Presentation August 2016
http://s2.q4cdn.com/790425727/files/doc_presentations/2016/INTELGENX_Aug-11.pdf
The wonder pill that could STOP your brain ageing: Common asthma drug may be a cure for Alzheimer's, claims study..
http://www.dailymail.co.uk/sciencetech/article-3290482/The-wonder-pill-STOP-ageing-Common-asthma-drug-cure-Alzheimer-s-claims-study.html
Alzheimer Phase 1 Results and Partner Deal for 3 Drugs coming within 4 weeks .
A lot of new Partnerdeals on the way which means Upfront Payments to the Company . Market Cap of $43 Million is still laughable for this Goldmine .GL
Transcript Q2 released last Thursday
http://s2.q4cdn.com/790425727/files/doc_financials/2016/final-081116-intelgenx-q2-2016-financial-results-47950179-v.3.pdf" rel="nofollow" target="_blank" >http://s2.q4cdn.com/790425727/files/doc_financials/2016/final-081116-intelgenx-q2-2016-financial-results-47950179-v.3.pdf
With respect to other BD activities, we're clearly focusing right now in the business development area on bringing in new deals. For example at the recent BIO Conference, we met with 50 different pharmaceutical companies to discuss partnering opportunities, and we're currently in discussions with eight companies that are interested in RIZAPORT licenses, 17 companies that are interested in our Tadalafil product, three companies are interested in our schizophrenia drug, and five companies have expressed interest in a deal on Forfivo outside of the US.
[B]Above and beyond that, there are ongoing late-stage discussions with a global pharmaceutical company for multiple products with the potential goal of finalizing a definitive agreement in the third quarter of 2016[/B]
.
Lot of new Partnerdeals coming , 2 new NDA Submission expected within 5 Months , enough Cash until mid 2018 and Market cap is still below $45 million thats really more than ridiculous .
The Company has now Cash untill mid 2018 excluding Upfront Payments from new Partnerships and Product Revenues . Partnerdeal news and Phase 1 Results of their Alzheimer Drug coming within 6 Weeks . Market Cap still way below $50 Million which is still a big Joke .
from yesterdays 2Q Results
http://www.intelgenx.com/investors/press-releases/press-release-details/2016/IntelGenx-Reports-Second-Quarter-2016-Financial-Results-and-Appointment-of-New-Director/default.aspx
Continued late-stage discussions with global pharmaceutical companies for multiple products with the potential goal of concluding a definitive agreement to be finalized in the third quarter of 2016
Initiated a phase 1 study of Montelukast for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia.IntelGenx expects results from the phase 1 trial to be available in September 2016.
What did you expect this is just Earnings nothing more . News like Partnership and Phase 1 results of their Alzheimer Drug coming within 6 Weeks .They have enough Cash until mid 2018 and FDA approval of their Opioid Dependence Drug could come anytime now ,this drug alone will push IGXT deep intoi profitability.
Market Cap is still way below $50 Million so this one is a Fantastic Opportunity .
Partnership news / NDA filing and potential FDA approval of opioid dependence drug all this could coe anyday now and willpush this stock much much higher .
Market cap of $44 Million is heavily underpriced for this Goldmine
Up she goes again and still brutally terrible underpriced
still think that $1 will fall this week
IGXT on the run ---10+ Bagger gem here (article)
IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus.....Tuesday, 09 Aug 2016
http://www.insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-is-todays-pharma-focus/116698/
Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it. We’ll know more after the markets close on August 11th when the company reports second quarter results and provides an update on the earnings call.
IGXT a 10 Bagger Gem (Article)
IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus.....Tuesday, 09 Aug 2016
http://www.insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-is-todays-pharma-focus/116698/
Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it. We’ll know more after the markets close on August 11th when the company reports second quarter results and provides an update on the earnings call.
IGXT a 10 Bagger Gem
IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus.....Tuesday, 09 Aug 2016
http://www.insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-is-todays-pharma-focus/116698/
Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it. We’ll know more after the markets close on August 11th when the company reports second quarter results and provides an update on the earnings call.
RALLYYYYYYYY
Nice Article
Shorts tried hard to kill momentum yesterday but they will lose the Game because the Stock is terrible Undervalued und there is to much News on the way so every dip below $1 is a great buying opportunity .
IntelGenx Technologies Corp (OTCMKTS:IGXT) Is Today’s Pharma Focus.....Tuesday, 09 Aug 2016
http://www.insiderfinancial.com/intelgenx-technologies-corp-otcmktsigxt-is-todays-pharma-focus/116698/
Currently trading with a market cap of $39 million, IGXT is one OTC pharma stock that has a lot in the pipeline. All it needs is one product to hit, and the company will be worth 10x its current market cap. IGXT has multi-bagger written all over it. We’ll know more after the markets close on August 11th when the company reports second quarter results and provides an update on the earnings call.
pullback creates a great buying opp
IGXT-DD UPDATE // LIFETIME OPPORTUNITY HERE
Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there are another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .Their unique Thin-film version of the Blockbuster Drug Cialis (Erectile Dysfunction) alone is worth $2-3 per share , NDA filing for the Drug coming before Year end .
IGXT has a ridiculous Market Cap of US$46 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL
Intelgenx (IGXT) (IGX.V)
Market Cap: $46 Million
Cash: $8.1 Million
Price: $0.72
Burn-Rate: ~$400k per Quarter
Shares Out : 63.6 Million
Upcoming Milestones :
Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q4/2016
•Expected USA launch Q2/2017
Product :Tadalafil (Erectile Dysfunction)
•505(b)(2) USA NDA submission in Q4/2016
•Expected USA launch Q4/2017
Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
IntelGenx to Initiate Phase 1 Trial of Montelukast
IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.
Presentation July 2016
http://s2.q4cdn.com/790425727/files/doc_presentations/2016/INTELGENX_July-6_2016-%281%29.pdf
The wonder pill that could STOP your brain ageing: Common asthma drug may be a cure for Alzheimer's, claims study..
http://www.dailymail.co.uk/sciencetech/article-3290482/The-wonder-pill-STOP-ageing-Common-asthma-drug-cure-Alzheimer-s-claims-study.html
Product Pipeline
$1+++ HERE WE COMEEEEEEEEE
Next CPXX here
The wonder pill that could STOP your brain ageing: Common asthma drug may be a cure for Alzheimer's, claims study
http://www.dailymail.co.uk/sciencetech/article-3290482/The-wonder-pill-STOP-ageing-Common-asthma-drug-cure-Alzheimer-s-claims-study.html
The Drug Montelukast mentioned above in the article alone is worth multiple times the current market cap of laughable $46 Million .If everything goes well with the potential Blockbuster Drug then IGXT will be the next Billion Dollar Company .
IntelGenx to Initiate Phase 1 Trial of Montelukast
http://www.intelgenx.com/investors/press-releases/press-release-details/2016/IntelGenx-to-Initiate-Phase-1-Trial-of-Montelukast/default.aspx
IntelGenx expects results from the phase 1 trial to be available in September 2016. Following the completion of the phase 1 results, the Company will begin preparation work to initiate a phase 2 study where patients will be enrolled. IntelGenx will be actively seeking a partnership or alliance opportunity to complete the remaining developmental work and commercialization of this product.
"Montelukast is by far the most important and promising drug repurposing opportunity that the company has in its product pipeline," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "IntelGenx with Dr. Aigner, is taking a leadership position in this most serious unmet need affecting millions globally. The market for degenerative diseases of the brain is a multi-billion-dollar opportunity for the company. We look forward to communicating the results from the phase 1 study and advancing montelukast forward to reach its full potential."
IGXT running higher guys
IGXT exploding again ..next week likely we will see $1++
RALLLYYYYYYYYYYYYYYYYYYYYYYYYYYYYY
REASONS TO BUY THIS GOLDMINE .................
Market Cap laughable $45 Million / Monster Pipeline / Lots of News around the corner = LIFETIMER OPP HERE
Upcoming Milestones :
Big Partnership imminent :
•Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016
Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q4/2016
•Expected USA launch Q2/2017
Product :Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
•505(b)(2) USA NDA submission in Q4/2016
•Expected USA launch Q4/2017
Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.
IGXT on the run again and still brutally undervalued
Market Cap laughable $42 Million / Monster Pipeline / Lots of News around the corner = LIFETIMER OPP HERE
image.slidesharecdn.com/intelgenxjuly620161-160706203825/95/intelgenx-investor-presentation-july-6-2016-6-638.jpg?cb=1467900821
Upcoming Milestones :
Big Partnership imminent :
•Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016
Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q4/2016
•Expected USA launch Q2/2017
Product :Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
•505(b)(2) USA NDA submission in Q4/2016
•Expected USA launch Q4/2017
Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.
IGXT on the run again and still terrible cheap with a market cap of laughable $44 million
this potential 10++ bagger is still unknown to most investors but they will buy at much higher price
i got it around 2 hours ago . i asked him why management is not buying more shares to bring back some confidence
Partnerdeal around the corner
Dear xxxxx,
Thank you for your email. At present insiders are in a black out period until the transaction with the major pharmaceutical company is concluded. As soon as we can be removed from the black out list we will begin purchasing shares.
Best regards,
cid:image001.png@01D1D22B.22A3C580
Edward Miller
Director, IR & Corporate Communications
6420 Abrams
buddy which stock is not pumped ???
here is an update for you
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124199965
look at their monster product pipeline with many attractive drugs close to market .This bio gem is currently one of the cheapest you can get at this time .
IGXT (MC $37 M) 2 FDA approvals coming + 2 new NDA Filings in 4Q = 1000% Potential A ONCE IN A LIFETIME OPP
Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there are another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .Their unique Thin-film version of the Blockbuster Drug Cialis (Erectile Dysfunction) alone is worth $2-3 per share , NDA filing for the Drug coming before Year end .
IGXT has a ridiculous Market Cap of $35 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL
Intelgenx (IGXT) (IGX.V)
Market Cap: $37 Million
Cash: $2.1 Million
Price: $0.59
Burn-Rate: ~$300k per Quarter
Shares Out : 63.6 Million
Upcoming Milestones :
Big Partnership imminent :
•Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016
Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q4/2016
•Expected USA launch Q2/2017
Product :Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
•505(b)(2) USA NDA submission in Q4/2016
•Expected USA launch Q4/2017
Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.
$1+ on the way market cap of $40 million still a mega joke
IGXT (MC $37 M) 2 FDA approvals coming + 2 new NDA Filings in 4Q = 1000% Potential...A REAL LIFETIME OPPORTUNITY GUYS
Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there are another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .Their unique Thin-film version of the Blockbuster Drug Cialis (Erectile Dysfunction) alone is worth $2-3 per share , NDA filing for the Drug coming before Year end .
IGXT has a ridiculous Market Cap of $35 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL
Intelgenx (IGXT) (IGX.V)
Market Cap: $37 Million
Cash: $2.1 Million
Price: $0.59
Burn-Rate: ~$300k per Quarter
Shares Out : 63.6 Million
Upcoming Milestones :
Big Partnership imminent :
•Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016
Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q4/2016
•Expected USA launch Q2/2017
Product :Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
•505(b)(2) USA NDA submission in Q4/2016
•Expected USA launch Q4/2017
Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.
Who is in IGXT ? I think this stock is currently one of the biggest opprtunity in the biotech area . check my previouspost for more infos .glta
IGXT (MC $37 M) 2 FDA approvals coming + 2 new NDA Filings in 4Q = 1000% Potential A LIFETIME OPPORTUNITY HERE
Undiscovered Intelgenx (IGXT) is definitely one of the most attractive and undervalued stock in the Biotech Sector . The Company has already 2 Drugs approved and another 2 Big Drugs close to FDA approval .BIG Partnership News could come any day for up to 3 Drugs for which IGXT got a Therm Sheet from a Global Pharma Company and there are another partnering discussion ongoing for 2 Drugs (see pipeline chart below) .Their unique Thin-film version of the Blockbuster Drug Cialis (Erectile Dysfunction) alone is worth $2-3 per share , NDA filing for the Drug coming before Year end .
IGXT has a ridiculous Market Cap of $35 Million which is a Big Joke for a Company with such a MEGA Product Pipeline , this Co has everything to be the next 10 Bagger minimum .GL
Intelgenx (IGXT) (IGX.V)
Market Cap: $37 Million
Cash: $2.1 Million
Price: $0.59
Burn-Rate: ~$300k per Quarter
Shares Out : 63.6 Million
Upcoming Milestones :
Big Partnership imminent :
•Announced a development and commercialization term sheet with a global pharmaceutical company for up to three products. If entered into, IntelGenx expects the definitive agreement to be finalized in the second quarter of 2016
Product :Rizaport (Migraine)
•European Mktg Approval–November 2015
•Planned USA submission to FDA Q4/2016
•Expected USA launch Q2/2017
Product :Tadalafil (Erectile Dysfunction) a better Oral thin-film version of Blockbuster Drug Cialis
•505(b)(2) USA NDA submission in Q4/2016
•Expected USA launch Q4/2017
Product :Indicated for Opioid Dependence
•Awaiting FDA approval
•According to IMS data, the oral film market for opioid dependence was worth more than $1.4B US in 2014.
IntelGenx Corp., today announced the recent initiation of a phase 1 clinical trial of montelukast, a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as: mild cognitive impairment and Alzheimers disease, the most prominent form of dementia. IntelGenx expects results from the phase 1 trial to be available in September 2016.
We could break 52 W high today ..Looking good again any news like Partnership or FDA approval and this will fly above $1++
$5++ Stock trading at 60 pennies because most investors didnt know this Goldmine but this will change very soon .
Kei what did $heff say ?